Viewing Study NCT03872661


Ignite Creation Date: 2025-12-24 @ 12:17 PM
Ignite Modification Date: 2025-12-27 @ 4:15 PM
Study NCT ID: NCT03872661
Status: RECRUITING
Last Update Posted: 2024-12-06
First Post: 2019-02-27
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Sponsor: Sun Yat-sen University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module